Wellington Management Group LLP Has $2.11 Billion Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Wellington Management Group LLP reduced its holdings in Edwards Lifesciences by 12.3%, owning 29.1 million shares worth approximately $2.11 billion after selling over 4 million shares in the first quarter.
• Edwards Lifesciences reported strong earnings, with an EPS of $0.67 for the last quarter, surpassing analyst estimates, and revenue of $1.53 billion, indicating a year-over-year growth of 11.9%.
• Many institutional investors are adjusting their positions, with 79.46% of the company’s stock now owned by hedge funds and institutions, reflecting significant interest in Edwards Lifesciences.

Wellington Management Group LLP lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 12.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,134,790 shares of the medical research company's stock after selling 4,076,089 shares during the quarter. Wellington Management Group LLP owned approximately 4.97% of Edwards Lifesciences worth $2,111,690,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Korea Investment CORP lifted its holdings in shares of Edwards Lifesciences by 37.5% during the 1st quarter. Korea Investment CORP now owns 647,275 shares of the medical research company's stock valued at $46,914,000 after acquiring an additional 176,625 shares in the last quarter. Aptus Capital Advisors LLC grew its position in shares of Edwards Lifesciences by 3.8% during the 1st quarter. Aptus Capital Advisors LLC now owns 10,386 shares of the medical research company's stock valued at $753,000 after buying an additional 385 shares during the last quarter. Watts Gwilliam & Co. LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $210,000. Granite Harbor Advisors Inc. grew its position in shares of Edwards Lifesciences by 10.2% during the 1st quarter. Granite Harbor Advisors Inc. now owns 4,989 shares of the medical research company's stock valued at $362,000 after buying an additional 462 shares during the last quarter. Finally, Versor Investments LP bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $1,123,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the sale, the vice president owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock worth $1,897,762 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

EW stock traded up $0.5950 on Friday, hitting $81.7550. 3,076,141 shares of the company's stock traded hands, compared to its average volume of 4,824,093. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The stock has a market cap of $48.00 billion, a price-to-earnings ratio of 11.76, a P/E/G ratio of 3.92 and a beta of 1.08. The stock has a fifty day moving average of $77.58 and a 200-day moving average of $74.68. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business earned $0.70 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Mizuho upped their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.